文献速递贫血与红细胞疾病

TPO-RA难治性再生障碍性贫血患者转换阿伐曲泊帕后的血液学反应

[Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性分析16例既往IST联合TPO-RA治疗无效或不耐受的再生障碍性贫血患者,转换为阿伐曲泊帕治疗至少6个月。难治组10例中7例(70%)获得三系血液学反应,不耐受组6例中4例(67%)获得血液学反应;未发生2级以上不良事件、血栓事件或骨髓纤维组织增生。

要点

  • 难治组10例转换阿伐曲泊帕后7例(70%)获得三系血液学反应,均在治疗3个月时开始起效。
  • 不耐受组6例中4例(67%)获得血液学反应,治疗6个月时4例均获得血液学反应。
  • 转换治疗过程中未发生阿伐曲泊帕相关2级以上不良事件,无血栓事件,骨髓病理未见纤维组织增生。

核心结论

  • 对于TPO-RA难治或不耐受的再生障碍性贫血患者,阿伐曲泊帕可作为较好的转换治疗选择。

研究设计与样本

  • 回顾性分析2021年1月至2021年12月中国医学科学院血液病医院收治的16例再生障碍性贫血患者。
  • 纳入既往IST联合TPO-RA(艾曲泊帕/海曲泊帕)治疗至少6个月但无效至少3个月,或因副作用无法继续使用TPO-RA而转换为阿伐曲泊帕治疗至少6个月的患者。
  • 16例患者中男、女各8例,中位年龄54(14~68)岁。

主要发现

  • 难治组10例转换阿伐曲泊帕中位治疗6(6~10)个月,7例(70%)获得三系血液学反应,其中完全治疗反应4例、良好治疗反应1例、部分治疗反应2例,均在阿伐曲泊帕治疗3个月时开始起效。
  • 不耐受组6例阿伐曲泊帕中位治疗6(2~8)个月,4例(67%)获得血液学反应,其中良好治疗反应3例、部分治疗反应1例。
  • 不耐受组中阿伐曲泊帕治疗3个月时2例获得部分治疗反应,6个月时4例患者均获得血液学反应。
  • 阿伐曲泊帕转换治疗过程中未发生阿伐曲泊帕相关2级以上不良事件,无血栓事件发生。
  • 治疗6个月时复查骨髓病理未见纤维组织增生,无一例患者因不良事件停药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Short-term efficacy and safety of afatrombopag conversion therapy in patients with aplastic anemia (AA) who were previously ineffectively treated with intense immunosuppressive therapy (IST) combined with TPO receptor Agonist (TPO-RA) or who were unable to tolerate the side effects of TPO-RA. Methods: Analysis of patients with severe aplastic anemia (SAA) treated in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College from January 2021 to December 2021 who received IST combined with TPO-RA (eltrombopag/hatrombopag) for at least 6 months, but was ineffective for at least 3 months or patients who cannot continue to use TPO-RA due to side effects, and switched from TPO-RA to avatrombopag (APAG) , and treated for at least 6 months. This study analyzed its short-term efficacy and evaluated its safety. Results: The median age was 54 (14-68) years old among the 16 patients with AA (8 male and eight female) . A total of ten patients (refractory group) who did not respond to IST combined with TPO-RA were converted to APAG median therapy for 6 (6-10) months. Only seven patients (70% ) obtained trilineage HR [four cases of complete treatment response (CTR) , one case of good treatment response (GPR) , and two cases of partial treatment response (PR) ], all of which began to take effect at 3 months of APAG treatment. There were six patients with TPO-RA intolerance, and APAG was treated for 6 (2 to 8) months. About four patients (67% ) received HR (three GPR cases and one PR case) , of which two patients received PR at 3 months and four patients received HR at 6 months of APAG treatment. No APAG-related grade 2 or more adverse events occurred during the APAG therapy, no thrombotic events occurred, no fibrologic tissue hyperplasia was found in the bone marrow pathology reexamination at 6 months of treatment, and none of the patients discontinued the drug due to adverse events. Conclusion: APAG may be a better switching treatment option for patients with AA who are refractory or are intolerant to TPO-RA. 目的: 评估阿伐曲泊帕(APAG)转换治疗在曾应用免疫抑制治疗(IST)联合TPO受体激动剂(TPO-RA)无效或TPO-RA不耐受的再生障碍性贫血(AA)患者中的近期疗效及安全性。 方法: 回顾性分析2021年1月至2021年12月中国医学科学院血液病医院(中国医学科学院血液学研究所)IST联合TPO-RA(艾曲泊帕/海曲泊帕)治疗无效或TPO-RA不耐受的16例AA患者,接受APAG转换治疗的疗效及安全性。 结果: 16例AA患者中,中位年龄54(14~68)岁,男、女各8例。IST联合TPO-RA治疗无效患者10例(难治组),转换APAG中位治疗6(6~10)个月,7例(70%)获得三系血液学反应(HR)[完全治疗反应(CR)4例、良好治疗反应(GPR)1例、部分治疗反应(PR)2例],均在APAG治疗3个月时开始起效;TPO-RA不耐受患者6例(不耐受组),APAG中位治疗6(2~8)个月,4例(67%)获得HR(GPR 3例、PR 1例),其中APAG治疗3个月时2例获得PR,6个月时4例患者均获得HR。APAG转换治疗过程中,未发生APAG相关2级以上不良事件,无血栓事件发生,治疗6个月时复查骨髓病理未见纤维组织增生,无一例患者因不良事件停药。 结论: 对于TPO-RA难治或不耐受的AA患者,APAG可作为较好的转换治疗选择。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jing LP, Fan HH, Yang WR, et al. [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709183. doi:10.3760/cma.j.issn.0253-2727.2022.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。